ストックスクリーナーアプリを入手
76.45
0.88%
-0.68
アフターアワーズ：
76.45
Cytokinetics Inc (CYTK) 最新ニュース
CYTK4910847 Bond Profile — Key Metrics - TradingView
Form 4 Cytokinetics Inc For: 27 July By Investing.com - Investing.com Canada
Cytokinetics (NASDAQ: CYTK) CEO sells 7,500 shares after option exercise - Stock Titan
Cytokinetics president & CEO Robert Blum sells $606,525 in stock By Investing.com - Investing.com Canada
Cytokinetics president & CEO Robert Blum sells $606,525 in stock - Investing.com
Cytokinetics Insider Sold Shares Worth $606,525, According to a Recent SEC Filing - Yahoo Finance
Cytokinetics Inc (CYTK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cytokinetics Inc (CYTK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cytokinetics Inc (CYTK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytokinetics Inc (CYTK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CYTK|Cytokinetics Inc|Price:80.740|Chg%:-1.180 - TradingKey
Cytokinetics Inc (CYTK) Balance Sheet - TradingKey
Cytokinetics, Incorporated Revenue Breakdown – BX:KK3A - TradingView
Cytokinetics, Incorporated Revenue Breakdown – FWB:KK3A - TradingView
Cytokinetics, Incorporated Revenue Breakdown – LS:A1W1KK - TradingView
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance UK
Cytokinetics EVP Fady Malik sells $282,065 in company stock By Investing.com - Investing.com Nigeria
Form 4 Cytokinetics Inc For: 24 July By Investing.com - Investing.com Nigeria
Cytokinetics EVP Fady Malik sells $282,065 in company stock - Investing.com
Cytokinetics Inc (CYTK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $282,065, According to a Recent SEC Filing - marketscreener.com
Cytokinetics to Announce Second Quarter Results on August 6, 2026 - The Manila Times
Cytokinetics Will Share Q2 Results Aug. 6, Then Host Live Call - Stock Titan
CYTK stock holds recent gains as Cytokinetics prepares next heart failure data readout - AD HOC NEWS
Cytokinetics Inc (CYTK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cytokinetics, Incorporated (CYTK) Options Chain - Yahoo! Finance Canada
Cytokinetics: Label Expansion Can Turn MYQORZO Into An HCM Franchise (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics' Myqorzo: The Challenger Drug Poised to Reshape a Multi-Billion Dollar Heart Market - Kavout | AI
Cytokinetics CEO on the launch of its first commercial drug - Yahoo Finance
Cytokinetics stock edges higher as cardiovascular pipeline and cash position underpin outlook - Ad-hoc-news.de
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Citi Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $99 - Moomoo
Form 4 Cytokinetics Inc For: 16 July By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) director Nancy Wysenski granted 75 fully vested shares - Stock Titan
Director stock grant at Cytokinetics (CYTK) highlights equity retainer - Stock Titan
Cytokinetics (CYTK) awards 151-share fully vested grant to director - Stock Titan
Cytokinetics Inc (CYTK) director granted 272 fully vested shares - Stock Titan
Cytokinetics (NASDAQ: CYTK) director receives 151-share equity retainer grant - Stock Titan
Cytokinetics (NASDAQ: CYTK) awards director 151 fully vested shares - Stock Titan
All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy - Yahoo Finance Singapore
Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet - Yahoo Finance
Braveheart files for IPO to fund Phase 3 of Hengrui’s Cytokinetics rival - Endpoints News
US23282WAC4 Bond Profile — Key Metrics - TradingView
Cytokinetics president & CEO Robert Blum sells $615,149 of stock - Investing.com UK
FMR LLC Reduces Stake in Cytokinetics Inc: A Detailed Analysis - GuruFocus
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% - The Motley Fool
Cytokinetics president & CEO Robert Blum sells $615,149 of stock By Investing.com - Investing.com South Africa
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% - The Motley Fool
Form 4 Cytokinetics Inc For: 14 July By Investing.com - Investing.com Nigeria
Cytokinetics Insider Sold Shares Worth $615,150, According to a Recent SEC Filing - Moomoo
Cytokinetics Inc (CYTK) CEO exercises options and sells 7,500 shares - Stock Titan
Will Myqorzo drive Cytokinetics higher despite competitive pressure? - MSN
1.84%
0.91%
大文字化:
|
ボリューム (24 時間):